We validated the FLT3-ITD/GRD association in an independent AML dataset profiling expression and drug response of ex vivo samples published by Tavor and colleagues14 (one-sided Wilcoxon rank-sum test p < 0.01; Supplementary Fig. 12). The gene discussed is FLT3; the disease is acute myeloid leukemia.